KalVista Pharmaceuticals (KALV) Misses Q2 EPS by 4c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.80), $0.04 worse than the analyst estimate of ($0.76).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge